Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

806 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine AJ, Andreeff M. Carter BZ, et al. Among authors: andreeff m. Blood. 2025 Jul 3:blood.2025028935. doi: 10.1182/blood.2025028935. Online ahead of print. Blood. 2025. PMID: 40608889
Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia.
Mamdouh AM, Lim FQ, Mi Y, Olesinski EA, Chan CGT, Jasdanwala S, Lin XX, Wang Y, Tan JYM, Bhatia KS, Sapozhnikova V, Wang C, Mahesh AN, Liang DTE, Chitkara N, Mertins P, Hogdal L, Brown BD, Haferlach T, Lobry C, Lindsley C, Puissant A, Ho HK, Das S, Letai A, Kornblau SM, Krönke J, Ayoub E, Itahana K, Andreeff M, Bhatt S. Mamdouh AM, et al. Among authors: andreeff m. bioRxiv [Preprint]. 2025 May 22:2025.05.17.654633. doi: 10.1101/2025.05.17.654633. bioRxiv. 2025. PMID: 40475516 Free PMC article. Preprint.
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias.
Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. Zhang W, et al. Among authors: andreeff m. Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-2764. Online ahead of print. Clin Cancer Res. 2025. PMID: 40327322
Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.
Akiyama H, Nishida Y, Chang KH, Bedoy AD, Muftuoglu M, Ma W, Basyal M, Hirschi Z, Honma D, Tsutsumi S, Wang J, Zhang W, Huang X, Rampal RK, Oluwole OO, Bixby DL, Daver NG, Andreeff M. Akiyama H, et al. Among authors: andreeff m. Blood Cancer J. 2025 Apr 24;15(1):76. doi: 10.1038/s41408-025-01266-0. Blood Cancer J. 2025. PMID: 40274779 Free PMC article. No abstract available.
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Daver N, et al. Among authors: andreeff m. Clin Cancer Res. 2025 Jun 13;31(12):2386-2398. doi: 10.1158/1078-0432.CCR-25-0229. Clin Cancer Res. 2025. PMID: 40198272 Clinical Trial.
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: andreeff m. Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25. Leukemia. 2025. PMID: 40000842 Free PMC article. Clinical Trial.
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. Bouligny IM, et al. Among authors: andreeff m. Haematologica. 2025 Jul 1;110(7):1628-1633. doi: 10.3324/haematol.2024.286559. Epub 2025 Feb 20. Haematologica. 2025. PMID: 39973365 Free PMC article. No abstract available.
806 results